Orchard Therapeutics Plc (ORTX) Misses Q4 EPS by 1c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q4 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c